Researchers at Leipzig University have identified a biological switch that could fundamentally change how doctors treat osteoporosis. By targeting a receptor known as GPR133, the team successfully increased bone density and repaired damage in animal models using a newly discovered compound called AP503.
The findings, published April 6, suggest that activating this receptor can restore the balance between bone-building cells and those that break down bone tissue. The discovery offers a potential path toward treatments that do more than just prevent further loss—they may actually rebuild bone.
Targeting the GPR133 receptor
Osteoporosis affects millions, particularly aging women, and current treatments often carry significant limitations. The research team focused on GPR133, a member of the adhesion G protein-coupled receptor family that sits on the surface of cells to transmit signals.
"If this receptor is impaired by genetic changes, mice show signs of loss of bone density at an early age—similar to osteoporosis in humans," said Professor Ines Liebscher, the study's lead investigator at the Rudolf Schönheimer Institute of Biochemistry.
Using computer-assisted screening, researchers identified AP503 as a compound capable of stimulating GPR133. When applied in studies, the compound promoted the activity of osteoblasts—the cells responsible for building bone—while inhibiting the osteoclasts that break it down.
The implications extend beyond skeletal health. Previous research by the Leipzig team indicated that activating GPR133 with AP503 also strengthens skeletal muscle. This dual effect could be critical for older adults, as it simultaneously addresses bone density and muscle strength to reduce the risk of fractures and falls.
"The newly demonstrated parallel strengthening of bone once again highlights the great potential this receptor holds for medical applications in an aging population," said Dr. Juliane Lehmann, the study's lead author.
The study is part of a decade-long project at Leipzig University focused on understanding how these receptors function. With the identification of AP503, the team is now moving to explore how this pathway might be utilized in broader clinical applications.
